77 related articles for article (PubMed ID: 25109334)
21. JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
Uckun FM; Pitt J; Qazi S
Expert Rev Anticancer Ther; 2011 Jan; 11(1):37-48. PubMed ID: 21070101
[TBL] [Abstract][Full Text] [Related]
22. Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.
Agarwal A; MacKenzie RJ; Eide CA; Davare MA; Watanabe-Smith K; Tognon CE; Mongoue-Tchokote S; Park B; Braziel RM; Tyner JW; Druker BJ
Oncogene; 2015 Jun; 34(23):2991-9. PubMed ID: 25109334
[TBL] [Abstract][Full Text] [Related]
23. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
24. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
[TBL] [Abstract][Full Text] [Related]
25. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
[TBL] [Abstract][Full Text] [Related]
26. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
[TBL] [Abstract][Full Text] [Related]
27. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
Yin C; Sandoval C; Baeg GH
Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
[TBL] [Abstract][Full Text] [Related]
28. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia.
Bellanger D; Jacquemin V; Chopin M; Pierron G; Bernard OA; Ghysdael J; Stern MH
Leukemia; 2014 Feb; 28(2):417-9. PubMed ID: 24048415
[No Abstract] [Full Text] [Related]
29. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia.
Sakaguchi H; Okuno Y; Muramatsu H; Yoshida K; Shiraishi Y; Takahashi M; Kon A; Sanada M; Chiba K; Tanaka H; Makishima H; Wang X; Xu Y; Doisaki S; Hama A; Nakanishi K; Takahashi Y; Yoshida N; Maciejewski JP; Miyano S; Ogawa S; Kojima S
Nat Genet; 2013 Aug; 45(8):937-41. PubMed ID: 23832011
[TBL] [Abstract][Full Text] [Related]
30. Signalling by the βc family of cytokines.
Hercus TR; Dhagat U; Kan WL; Broughton SE; Nero TL; Perugini M; Sandow JJ; D'Andrea RJ; Ekert PG; Hughes T; Parker MW; Lopez AF
Cytokine Growth Factor Rev; 2013 Jun; 24(3):189-201. PubMed ID: 23535386
[TBL] [Abstract][Full Text] [Related]
31. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
32. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
[TBL] [Abstract][Full Text] [Related]
33. Targeting acute myeloid leukemia cells with cytokines.
Ferretti E; Cocco C; Airoldi I; Pistoia V
J Leukoc Biol; 2012 Sep; 92(3):567-75. PubMed ID: 22591693
[TBL] [Abstract][Full Text] [Related]
34. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia.
Bains T; Heinrich MC; Loriaux MM; Beadling C; Nelson D; Warrick A; Neff TL; Tyner JW; Dunlap J; Corless CL; Fan G
Leukemia; 2012 Sep; 26(9):2144-6. PubMed ID: 22425895
[No Abstract] [Full Text] [Related]
35. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia.
Blink M; Buitenkamp TD; van den Heuvel-Eibrink MM; Danen-van Oorschot AA; de Haas V; Reinhardt D; Klusmann JH; Zimmermann M; Devidas M; Carroll AJ; Basso G; Pession A; Hasle H; Pieters R; Rabin KR; Izraeli S; Zwaan CM
Leukemia; 2011 Aug; 25(8):1365-8. PubMed ID: 21537335
[No Abstract] [Full Text] [Related]
36. Treating inflammation with the Janus kinase inhibitor CP-690,550.
Vijayakrishnan L; Venkataramanan R; Gulati P
Trends Pharmacol Sci; 2011 Jan; 32(1):25-34. PubMed ID: 21144599
[TBL] [Abstract][Full Text] [Related]
37. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP.
Ju W; Zhang M; Jiang JK; Thomas CJ; Oh U; Bryant BR; Chen J; Sato N; Tagaya Y; Morris JC; Janik JE; Jacobson S; Waldmann TA
Blood; 2011 Feb; 117(6):1938-46. PubMed ID: 21106989
[TBL] [Abstract][Full Text] [Related]
38. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
39. JAK3: a two-faced player in hematological disorders.
Cornejo MG; Boggon TJ; Mercher T
Int J Biochem Cell Biol; 2009 Dec; 41(12):2376-9. PubMed ID: 19747563
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
